Compare Incyte Corporation (INCY) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Schwab US Dividend Equity ETF — how do they compare? Incyte Corporation trades at $120.61 (market cap $24.54B), while Schwab US Dividend Equity ETF trades at $34.26. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | SCHD | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $34.27 |
52-Week Low | $81.61 | $26.44 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
SCHD trades at $34.225, up 0.1% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF's dividend strategy remains a core appeal, highlighted by a scheduled $0.25 dividend in June 2026. Recent news emphasizes its role in retirement income portfolios and institutional accumulation, such as Barry Investment Advisors increasing its stake by 29.9% in Q2 2026.
Outlook is supported by dividend reliability and value rotation trends, but risks include yield competition from Treasuries and tax inefficiencies in taxable accounts. The ETF suits income-focused investors seeking steady payouts, though overbought conditions may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
